Atlas Trials

Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

Clinical trial NCT05213637 · UNKNOWN

Trial details

NCT number
NCT05213637
Sponsor
Chinese PLA General Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma (HCC)
Start date
2018-04-25
Primary completion
2022-06-30
Enrollment
430

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.